Pseudotumor Cerebri, also known as idiopathic intracranial hypertension (IIH) is a syndrome of elevated intracranial pressure (ICP) that occurs predominantly in obese women of childbearing age. Headaches and vision impairment are most commonly found in patients with Pseudotumor Cerebri. The visual symptoms may arise due to papilledema.
It is noted that rising technological advancements and increasing prevalence of obesity are the key factors driving the pseudotumor cerebri market. According to the statistics suggested by WHO, more than 1.9 billion individuals were overweight, and out of these over 650 million bordered obesity, in 2016. It is also estimated that more than 340 million children and adolescents were overweight or obese in 2016. It is also observed that various health conditions such as sleep apnea, Addison's disease, kidney disease, and Lyme disease also escalate the risk of pseudotumor cerebri.
Various other factors such as growing awareness, the increased incidence of pseudotumor cerebri, and related complications, unmet medical needs, enhancing regulatory framework, the increasing adoption rate of new technology, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the global pseudotumor cerebri market.
Despite these drivers, there are some setbacks associated with pseudotumor cerebri market. The cost of treatment, side-effects associated with surgical interventions, and poor healthcare system in the low and middle-income countries may hinder the growth of the market to a considerable extent.
It is estimated that the Pseudotumor Cerebri market is expected to grow at a CAGR 6.0% during the forecast period of 2017-2023.
Segmentation
The global pseudotumor cerebri market is segmented by diagnosis, treatment, and end user.
By the diagnosis, the market is classified as fundoscopy, neuroimaging, lumbar puncture, and others.
By the treatment, the market is classified as surgery, medication, and others. The surgery is further segmented into the spinal fluid shunt, optic nerve sheath fenestration (ONSF), dural venous sinus stenting, and bariatric surgery. The medication is further segmented into acetazolamide, topiramate, furosemide, steroids, others.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Key Players
Some of key the players in the global pseudotumor cerebri market are Avkare, Inc, B. Braun Melsungen AG, Beckersmith Medical, Inc, Elekta AB, Heritage Pharmaceuticals Inc, Ingenus Pharmaceuticals, Integra LifeSciences Corporation, Johnson & Johnson Services, Inc., Lannett Company, Inc., Magstim, Medtronic, MercuryPharma, Nostrum Laboratories Inc, Novast Holdings Ltd., Phoenix Biomedical Corp., Sanofi, SGPharma Pvt. Ltd., Sophysa, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, West-Ward Pharmaceutical, Zydus Pharmaceuticals, Inc., and others.
Request Customization
Get a Sample
Get a Sample
Request Customization